MAGEA3 Antikörper (AA 283-314)

Produktnummer ABIN7873309

Der Kaninchen Polyklonal anti-MAGEA3 Antikörper (ABIN7873309) detektiert spezifisch MAGEA3 in WB, FACS und IHC (p). Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für MAGEA3 Antikörper (AA 283-314) (ABIN7873309)

Target: MAGEA3 (Melanoma Antigen Family A, 3 (MAGEA3))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser MAGEA3 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Produktdetails anti-MAGEA3 Antikörper

Bindungsspezifität: AA 283-314

Verwendungszweck: MAGE3 Antibody / Melanoma-associated antigen 3

Immunogen: A portion of amino acids 283-314 from the human protein was used as the immunogen for the MAGE3 antibody.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: The stated application concentrations are suggested starting points. Titration of the MAGE3 antibody may be required due to differences in protocols and secondary/substrate sensitivity.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot the MAGE3 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Details zu MAGEA3

Target: MAGEA3 (Melanoma Antigen Family A, 3 (MAGEA3))

Andere Bezeichnung: MAGE3

Hintergrund: MAGE3, also known as Melanoma-associated antigen 3, is a protein that is commonly expressed in melanoma cells. It plays a crucial role in tumor growth and progression, making it an attractive target for cancer therapy. Research has shown that targeting MAGE3 can effectively inhibit the growth of melanoma cells, leading to the potential development of new treatments for this aggressive form of cancer. One of the most exciting aspects of MAGE3 is its ability to stimulate the immune system to recognize and attack cancer cells. This makes it a promising candidate for immunotherapy, a cutting-edge treatment that harnesses the power of the body's own immune system to fight cancer. By targeting MAGE3, researchers hope to develop more effective and targeted therapies for melanoma patients. Recent studies have highlighted the potential of MAGE3 as a biomarker for predicting the prognosis of melanoma patients. By measuring the levels of MAGE3 in tumor samples, doctors can better tailor treatment plans and improve patient outcomes.

UniProt: P43357